

Supplementary Table 1: Diet Formulation

| Ingredients | Control Diet (AIN-93M) | TC Diet (10%) | FOS Diet (10%) |
|---|---------------------------|------------------|-------------------|
| | (g/kg diet) | (g/kg diet) | (g/kg diet) |
| TC¹ or FOS | 0.0 | 100.0 | 100.0 |
| Carbohydrates | | | |
| Cornstarch (g) | 465.7 | 383.6 | 365.7 |
| Maltodextrin (g) | 155.0 | 155.0 | 155.0 |
| Sucrose (g) | 100.0 | 100.0 | 100.0 |
| TC (g) | 0.0 | 82.1 | |
| Protein | | | |
| Casein (g) | 140.0 | 133.5 | 140.0 |
| TC (g) | 0.0 | 6.5 | |
| Fat | | | |
| Soybean oil (g) | 40.0 | 39.4 | 40.0 |
| TC (g) | 0.0 | 0.59 | |
| Fiber | | | |
| Cellulose(g) | 50.0 | 48.1 | 50.0 |
| TC (g) | 0.0 | 1.92 | |
| Vitamin mix | 10.0 | 10.0 | 10.0 |
| Mineral | | | |
| Mineral mix ² | 13.4 | 13.4 | 13.4 |
| Calcium Carbonate (40.04% Ca) | 12.5 | 12.3 | 12.5 |
| Sodium Phosphate, monobasic (25.81 % P) | 5.6 | 5.5 | 5.6 |
| Potassium Phosphate, monobasic (22.76% P) | 2.4 | 2.4 | 2.4 |
| Sucrose | 1.1 | 1.3 | 1.1 |
| Choline Bitartrate | 2.5 | 2.5 | 2.5 |
| L-cysteine | 1.8 | 1.8 | 1.8 |

¹TC (tart cherry) analysis performed by NP Analytical Laboratories (St Louis, MO).² Calcium and phosphorus deficient mineral mix (TD 98057 Envigo Laboratories) was used so that calcium and phosphorus could be adjusted for the TC diet.

Supplementary Table 2: Primer Sequence List for qRT-PCRs

| Symbol | Name | Sequence |
|-------------------------|--|--|
| <i>Bmp2</i> | Bone morphogenetic protein 2 | QF 5'- GGACATCCGCTCCACAAA -3' QR 5'- GGCCTTCGCTGTTT-3' |
| <i>Bsp</i> | Bone sialoprotein | QF 5'- ACACCCCCAAGCACAGACTTTG -3' QR 5'- TCCTCGTCGCTTCCTTCACT -3' |
| <i>Ccr7</i> | C-C Motif Chemokine Receptor 7 | QF 5'- GGTGGCTCTCCTTGTCATTTC -3' QR 5'- GTGGTATTCTCGCCGATGTAGTC -3' |
| <i>Colla1</i> | Type I collagen called the pro- α 1 | QF 5'- CGTCTGGTTGGAGAGAGCAT -3' QR 5'- GGTCAAGCTGGATAGCGACATC -3' |
| <i>Cx43</i> | Connexin 43 | QF 5'- ACAGCGGTTGAGTCAGCTT-3' QR 5'- GAGAGATGGGAAGGACTTGT-3' |
| <i>Cxc12</i> | C-X-C Motif Chemokine Ligand 12 | QF 5'- CAAGCATCTGAAAATCCTAACAC -3' QR 5'- TCTTCAGCCGTGCAACAATC -3' |
| <i>Cxcl10</i> | C-X-C Motif Chemokine Ligand 10 | QF 5'- AGTGCCTGCCGTCACTTCTG -3' QR 5'- ATTCTCACTGGCCCCTCAT-3' |
| <i>Cxcr4</i> | C-X-C Motif Chemokine Receptor 4 | QF 5'- TCAGTGGCTGACCTCCTCTT -3' QR 5'- CTTGGCCTTGACTGTTGGT-3' |
| <i>Dmp-1</i> | Dentin matrix acidic phospho protein 1 | QF 5'- CTGTCATTCTCCTTGTTCCCT -3' QR 5'- CAAATCACCCGCTCTCTTC -3' |
| <i>Gapdh</i> | Glucose 6 phosphate dehydrogenase | QF 5'- GAACGCAAAGCTGAAGTGAGACT -3' QR 5'- TCATTACGCTTGCAC TGTTGGT -3' |
| <i>Gpr41</i> | G protein-coupled receptor 41 | QF 5'- TCCTGGCATCGGCTCACT -3' QR 5'- TGTAGGTTGCATTCCCCAGTA -3' |
| <i>Gpr43</i> | G protein-coupled receptor 43 | QF 5'- TTCCCCTGGCAGTCACCCT -3' QR 5'- GGGCTGCGTGAGCATGAT -3' |
| <i>Gpr109a</i> | G protein-coupled receptor 109a | QF 5'- TCGAAAGAAAACATTGGGTGAA -3' QR 5'- CCCCGTGAGCTCCACACT-3' |
| <i>Hprt1</i> | Hypoxanthine-guanine phosphoribosyl transferase | QF 5'- GCCTAAGATGAGCGCAAGTTG -3' QR 5'- TACTAGGCAGATGCCACAGG -3' |
| <i>Il6</i> | Interleukin 6 | QF 5'- GAGGATACCCTCCAAACAGACC -3' QR 5'- AAGTGCATCATCGTTGTCATAACA -3' |
| <i>Il10</i> | Interleukin 10 | QF 5'- GGTTGCCAAGCCTTATCGGA -3' QR 5'- ACCTGCTCCACTGCCTTGCT -3' |
| <i>Il17</i> | Interleukin 17 | QF 5'- ATCCCTCAAAGCTCAGCGTGTC -3' QR 5'- GGGCTCTCATTGCGGTGGAGAG-3' |
| <i>Il22</i> | Interleukin 22 | QF 5'- TGCCTTCCTGACCAAACCTCA -3' QR 5'- CTGGTCGTGACCGCTGATG -3' |
| <i>Il23</i> | Interleukin 23 | QF 5'- CGCCAAGGTCTGGCTTTTAT -3' QR 5'- CAGGCTCCCCTTGAAGATG -3' |
| <i>Mepe</i> | Matrix extracellular phospho glycoprotein | QF 5'- CCCCAAGAGCAGCAAAGGTA -3' QR 5'- CTCCGCTGTGACATCCCTTA -3' |
| <i>Ocn (Bglap2)</i> | Osteocalcin (Bone gamma-carboxyglutamate protein 2 | QF 5'- TGAGCTTAACCTGCTTGTGACGA -3' QR 5'- AGGGCAGCACAGGTCTAAATAGT -3' |
| <i>Opg</i> | Osteoprotegerin | QF 5'- TCCCGAGGACCACAATGAAC -3' QR 5'- TGGGTITGTCCATTCAATGATGT -3' |
| <i>Opn</i> | Osteopontin | QF 5'- ACTCCAATCGTCCCTACAGTCG -3' QR 5'- TGAGGTCCTCATCTGTGGCAT -3' |
| <i>Osx</i> | Osterix | QF 5'- GAAGTTCACCTGCCTGCTCTGT -3' QR 5'- CGTGGGTGCGCTGATGT -3' |
| <i>Phex</i> | Phosphate regulating endopeptidase X linked | QF 5'- GGCATGACTGCTGTAAGATCAGAT -3' QR 5'- AGCTCCATTGACATAAGGCACT -3' |

| | | |
|---------------|--|---|
| <i>Rankl</i> | Receptor activator of nuclear factor kappa-B ligand | QF 5'- TCTGCAGCATCGCTCTGTTCTGATATT- 3' QR 5'- AGCA GTGAGTGCTGTCTGATATT- 3' |
| <i>Runx2</i> | Runt-related transcription factor 2 | QF 5'- CGACAGTCCCAACTCCTGT-3' QR 5'- CGGTAACCACAGTCCCACATCT -3' |
| <i>Sost</i> | Sclerostin | QF 5'- ACCGGGCGGAGAATGG -3' QR 5'- GCTGTACTCGGACACATTTGG -3' |
| <i>Tgfb</i> | Transforming growth factor beta | QF 5'- CCCTATATTGGAGCCTGGA -3' QR 5'- CTTGCGACCCACGTAGTAGA -3' |
| <i>Tnfa</i> | Tumor necrosis factor alpha | QF 5'- CTGAGGTCAATCTGCCCAAGTAC -3' QR 5'- CTTCACAGAGCAATGACTCCAAAG-3' |
| <i>Vcam1</i> | Vascular Cell Adhesion Molecule 1 | QF 5'- TGAACCCAACAGAGGGAGAGT -3' QR 5'- GGTATCCCACACTTGAGCAGG -3' |
| <i>Wnt10b</i> | Wingless-type MMTV integration site family, member 10b | QF 5'- ATGCGGATCCACAACAAACAG-3' QR 5'- TTCCATGGCATTGCACTTC- 3' |

Supplementary Table 3: Additional Trabecular and Cortical Bone Microarchitectural Parameters of the Lumbar Vertebra and Tibia

| | Con | | TC | | FOS | | P-values | | |
|----------------------------------|---------------|---------------|---------------------------|---------------------------|-------------------------------|-------------------------------|----------|---------|-----------|
| | - CD25 | + CD25 | - CD25 | + CD25 | - CD25 | + CD25 | CD25 | Diet | CD25*Diet |
| Vertebra Trabecular Bone | | | | | | | | | |
| TbN (1/mm ²) | 4.18 ± 0.07 | 4.29 ± 0.10 | 4.20 ± 0.08 | 4.46 ± 0.01 | 5.00 ± 0.07 ^{#\$} | 4.97 ± 0.11 ^{#\$} | 0.1238 | <0.0001 | 0.2547 |
| TbTh (μm) | 51.58 ± 0.79 | 51.55 ± 1.04 | 49.36 ± 0.57 [#] | 49.95 ± 0.89 [#] | 55.08 ± 0.37 ^{#\$} | 54.88 ± 0.91 ^{#\$} | 0.8579 | <0.0001 | 0.8764 |
| TbSp (μm) | 238.00 ± 4.35 | 230.38 ± 6.45 | 232.86 ± 4.47 | 222.88 ± 5.30 | 196.13 ± 3.44 ^{#\$} | 198.63 ± 5.68 ^{#\$} | 0.2317 | <0.0001 | 0.2317 |
| ConnDens (1/mm ³) | 160.48 ± 7.66 | 164.89 ± 7.40 | 158.07 ± 5.37 | 187.15 ± 7.30 | 240.54 ± 9.97 ^{#\$} | 241.51 ± 14.92 ^{#\$} | 0.1026 | <0.0001 | 0.1414 |
| SMI | 1.28 ± 0.07 | 1.36 ± 0.06 | 1.46 ± 0.02 [#] | 1.46 ± 0.07 [#] | 0.73 ± 0.04 ^{#\$} | 0.70 ± 0.09 ^{#\$} | 0.8116 | <0.0001 | 0.5710 |
| Tibia Trabecular Bone | | | | | | | | | |
| TbN (1/mm ²) | 3.84 ± 0.08 | 3.79 ± 0.13 | 3.76 ± 0.10 | 3.64 ± 0.09 | 4.39 ± 0.10 ^{#\$} | 4.51 ± 0.08 ^{#\$} | 0.8119 | <0.0001 | 0.4473 |
| TbTh (μm) | 47.22 ± 0.68 | 45.19 ± 0.89 | 45.74 ± 1.31 | 45.40 ± 1.10 | 47.69 ± 0.64 ^{\$} | 48.18 ± 0.65 ^{\$} | 0.3937 | 0.0330 | 0.3581 |
| TbSp (μm) | 255.43 ± 5.00 | 259.94 ± 9.18 | 261.88 ± 7.07 | 270.14 ± 6.88 | 219.78 ± 5.54 ^{#\$} | 212.53 ± 3.98 ^{#\$} | 0.7301 | <0.0001 | 0.4665 |
| ConnDens (1/mm ³) | 81.73 ± 4.69 | 78.67 ± 7.40 | 93.10 ± 9.34 | 81.66 ± 6.02 | 145.96 ± 12.34 ^{#\$} | 154.87 ± 7.22 ^{#\$} | 0.5925 | <0.0001 | 0.4719 |
| SMI | 2.14 ± 0.10 | 2.17 ± 0.06 | 1.99 ± 0.09 [#] | 1.97 ± 0.04 [#] | 1.83 ± 0.08 ^{#\$} | 1.80 ± 0.04 ^{#\$} | 0.8420 | 0.0001 | 0.9173 |
| Tibia Cortical Bone | | | | | | | | | |
| MedullaryArea (μm ²) | 28.1 ± 0.60 | 27.90 ± 0.80 | 27.7 ± 0.60 | 27.60 ± 1.10 | 30.9 ± 0.70 ^{#\$} | 29.10 ± 0.70 ^{#\$} | 0.3417 | 0.0076 | 0.4884 |
| Porosity (%) | 3.88 ± 0.06 | 3.93 ± 0.11 | 3.93 ± 0.04 | 3.77 ± 0.12 | 4.1 ± 0.10 | 4.07 ± 0.13 | 0.2124 | 0.0809 | 0.7615 |

Control diet = Con; Tart cherry diet = TC; Fructooligosaccharide diet = FOS; Isotype control antibody = - CD25; CD25 antibody = +CD25.

Data presented as mean ± SE. n=8 mice/group. When only main effects of diet were detected, # indicates differences between TC or FOS diets vs. Con diet ($P<0.05$). \$ indicated differences between TC vs. FOS diet groups ($P<0.05$).

Supplementary Table 4: T-Lymphocyte Absolute Counts in Ileum and Bone Marrow

| | Con | | TC | | FOS | | P-values | | |
|---|---------------------------|------------------------|------------------------|-------------------------|-----------------------------|-----------------------------|----------|---------|-----------|
| | - CD25 | + CD25 | - CD25 | + CD25 | - CD25 | + CD25 | CD25 | Diet | CD25*Diet |
| Ileum T-Lymphocytes | | | | | | | | | |
| CD3 ⁺ CD4 ⁺ (1 x 10 ³) | 15.43 ± 3.42 | 27.00 ± 6.12 | 18.90 ± 3.32 | 18.17 ± 2.56 | 10.77 ± 1.27 | 14.84 ± 2.82 | 0.0743 | 0.1048 | 0.4038 |
| Treg (CD4 ⁺ CD25 ⁺ Foxp3 ⁺) | 431 ± 102.31 ^b | 55 ± 12 ^c | 821 ± 129 ^a | 23 ± 7.01 ^d | 457 ± 53 ^{ab} | 26 ± 4.01 ^{cd} | <0.0001 | 0.8014 | 0.0030 |
| Th-17 (CD4 ⁺ IL-17 ⁺) | 163 ± 40 ^b | 223 ± 59 ^{ab} | 168 ± 48 ^b | 87 ± 19.34 ^b | 126 ± 28 ^b | 358 ± 44.98 ^a | 0.0998 | 0.0848 | 0.0131 |
| Bone Marrow T-Lymphocytes | | | | | | | | | |
| CD3 ⁺ CD4 ⁺ (1 x 10 ³) | 4.47 ± 0.85 | 3.40 ± 0.94 | 5.52 ± 1.16 | 3.79 ± 0.41 | 14.15 ± 1.10 ^{#\$} | 10.64 ± 0.92 ^{#\$} | 0.0391 | <0.0001 | 0.7621 |
| Treg (CD4 ⁺ CD25 ⁺ Foxp3 ⁺) | 886 ± 165 | 6.75 ± 3.74 | 788 ± 202 | 3.5 ± 1.43 | 2566 ± 121 ^{#\$} | 11.83 ± 2.18 ^{#\$} | <0.0001 | <0.0001 | 0.2407 |
| Th-17 (CD4 ⁺ IL-17 ⁺) | 60 ± 14 | 61 ± 20 | 54 ± 11.61 | 57 ± 15 | 147 ± 26 ^{#\$} | 163 ± 19.66 ^{#\$} | 0.9469 | <0.0001 | 0.6876 |

Control diet = Con; Tart cherry diet = TC; Fructooligosaccharide diet = FOS; Isotype control antibody = - CD25; CD25 antibody = +CD25.

Data presented as mean ± SE. n=8/group. Superscript letters note significant interactions (CD25*Diet) and groups that share the same superscript letter are not significantly different from each other. When only main effects of diet were detected, # indicates differences between TC or FOS diets vs. Con diet ($P<0.05$). \$ indicates differences between the TC vs. FOS diet groups ($P<0.05$).

Supplementary Table 5: Bone Gene Expression Data

| | Con | | FOS | | P-values | | |
|-----------------------------|-------------|-------------|-------------|-------------|----------|--------|-----------|
| | - CD25 | + CD25 | - CD25 | + CD25 | CD25 | Diet | CD25*Diet |
| Osteoblastogenesis | | | | | | | |
| <i>Runx 2</i> | 1.00 ± 0.14 | 1.38 ± 0.15 | 1.39 ± 0.17 | 1.12 ± 0.21 | 0.8852 | 0.5806 | 0.1806 |
| Osteoblast Markers | | | | | | | |
| <i>Bsp</i> | 1.00 ± 0.23 | 1.10 ± 0.15 | 1.78 ± 0.31 | 0.93 ± 0.16 | 0.2121 | 0.4246 | 0.0923 |
| <i>Bglap2</i> | 1.00 ± 0.18 | 1.59 ± 0.22 | 2.15 ± 0.38 | 1.87 ± 0.48 | 0.8661 | 0.0848 | 0.3625 |
| <i>Opn</i> | 1.00 ± 0.19 | 0.85 ± 0.15 | 1.52 ± 0.23 | 0.93 ± 0.18 | 0.1563 | 0.2700 | 0.3641 |
| Rank: Rankl:Opg Axis | | | | | | | |
| <i>RankL</i> | 1.00 ± 0.16 | 0.91 ± 0.1 | 0.90 ± 0.22 | 0.81 ± 0.12 | 0.7798 | 0.1754 | 0.8669 |
| <i>Opg</i> | 1.00 ± 0.11 | 0.74 ± 0.17 | 1.01 ± 0.27 | 0.73 ± 0.12 | 0.3621 | 0.8459 | 0.3917 |
| <i>RankL:Opg</i> | 1.00 ± 0.27 | 1.48 ± 0.37 | 0.72 ± 0.06 | 1.63 ± 0.15 | 0.0820 | 0.2180 | 0.4943 |

Control diet = Con; Fructooligosaccharide diet = FOS; Isotype control antibody = - CD25; CD25 antibody = +CD25.

Data presented as mean ± SE. n=6/group

Supplementary Figure 1.

Representative 3-D images generated from microCT scans of the (A) lumbar vertebral body and (B) midshaft of the tibia. Control diet = Con; Tart cherry diet = TC; Fructo-oligosaccharide diet = FOS; Isotype control antibody = -CD25; CD25 antibody = +CD25.

